Novadaq Technologies Inc. (NASDAQ:NVDQ) (TSE:NDQ) has been assigned an average rating of “Hold” from the sixteen brokerages that are covering the company, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, thirteen have given a hold recommendation and two have given a buy recommendation to the company. The average twelve-month price target among brokers that have covered the stock in the last year is $12.00.

NVDQ has been the topic of a number of research analyst reports. First Analysis cut shares of Novadaq Technologies from an “overweight” rating to an “equal weight” rating in a report on Tuesday, June 20th. Royal Bank Of Canada cut shares of Novadaq Technologies from an “outperform” rating to a “sector perform” rating and cut their price objective for the stock from $12.00 to $11.75 in a report on Thursday, July 13th. Canaccord Genuity reissued a “buy” rating and set a $10.00 price objective on shares of Novadaq Technologies in a report on Monday, June 19th. JMP Securities reissued a “market perform” rating on shares of Novadaq Technologies in a report on Thursday, July 13th. Finally, Wedbush cut shares of Novadaq Technologies from an “outperform” rating to a “neutral” rating in a report on Monday, June 19th.

Novadaq Technologies (NASDAQ NVDQ) opened at 11.75 on Wednesday. The firm’s market cap is $679.41 million. Novadaq Technologies has a 52 week low of $5.84 and a 52 week high of $12.74. The firm’s 50-day moving average is $11.68 and its 200-day moving average is $9.03.

Several institutional investors have recently made changes to their positions in the company. JPMorgan Chase & Co. increased its holdings in shares of Novadaq Technologies by 4.8% in the 2nd quarter. JPMorgan Chase & Co. now owns 5,308,769 shares of the medical research company’s stock valued at $62,219,000 after acquiring an additional 243,261 shares during the period. FMR LLC grew its position in Novadaq Technologies by 30.5% in the 1st quarter. FMR LLC now owns 3,107,271 shares of the medical research company’s stock valued at $24,206,000 after buying an additional 726,288 shares during the last quarter. Janus Henderson Group PLC purchased a new position in Novadaq Technologies in the 2nd quarter valued at $32,663,000. Clearbridge Investments LLC grew its position in Novadaq Technologies by 0.4% in the 1st quarter. Clearbridge Investments LLC now owns 2,554,843 shares of the medical research company’s stock valued at $19,902,000 after buying an additional 9,371 shares during the last quarter. Finally, Sand Grove Capital Management LLP purchased a new position in Novadaq Technologies in the 2nd quarter valued at $27,072,000. 75.38% of the stock is currently owned by institutional investors and hedge funds.

TRADEMARK VIOLATION NOTICE: “Novadaq Technologies Inc. (NVDQ) Receives Consensus Recommendation of “Hold” from Analysts” was first posted by American Banking News and is the property of of American Banking News. If you are viewing this piece on another website, it was illegally stolen and reposted in violation of U.S. & international copyright legislation. The original version of this piece can be viewed at https://www.americanbankingnews.com/2017/10/11/novadaq-technologies-inc-nvdq-receives-consensus-recommendation-of-hold-from-analysts.html.

Novadaq Technologies Company Profile

NOVADAQ Technologies Inc is a medical device company. The Company primarily develops, manufactures and markets real-time fluorescence imaging products that are designed for use by surgeons in the operating room and other clinical settings where open and minimally invasive surgery or interventional procedures are performed.

Analyst Recommendations for Novadaq Technologies (NASDAQ:NVDQ)

Receive News & Ratings for Novadaq Technologies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novadaq Technologies Inc. and related companies with MarketBeat.com's FREE daily email newsletter.